| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Debasis Sen, Sunny Rathee, Vishal Pandey, Sanjay K Jain, Umesh K Pati. Comprehensive Insights into Pathophysiology of Alzheimer's Disease: Herbal Approaches for Mitigating Neurodegeneration. Current Alzheimer research. 2024-04-16. PMID:38623983. |
this review explores the multifaceted pathophysiology of ad, focusing on key hypotheses such as the cholinergic hypothesis, hyperphosphorylated tau protein and amyloid β hypothesis, oxidative stress hypothesis, and the metal ion hypothesis. |
2024-04-16 |
2024-04-18 |
Not clear |
| Xiyong Xiang, Siyu Xia, Shan Li, Yirong Zeng, Lixuan Wang, Yan Zho. Study on the role and mechanism of Tan IIA in Alzheimer's disease based on CREB-BDNF-TrkB pathway. Neuroscience letters. 2024-04-14. PMID:38616003. |
the occurrence and development of alzheimer's disease (ad) is closely related to neuronal loss, inflammatory response, cholinergic imbalance, and tau protein hyperphosphorylation. |
2024-04-14 |
2024-04-17 |
rat |
| Maciej Zadrozny, Patrycja Drapich, Anna Gasiorowska-Bien, Wiktor Niewiadomski, Charles R Harrington, Claude M Wischik, Gernot Riedel, Grazyna Niewiadomsk. Neuroprotection of Cholinergic Neurons with a Tau Aggregation Inhibitor and Rivastigmine in an Alzheimer's-like Tauopathy Mouse Model. Cells. vol 13. issue 7. 2024-04-12. PMID:38607082. |
neuroprotection of cholinergic neurons with a tau aggregation inhibitor and rivastigmine in an alzheimer's-like tauopathy mouse model. |
2024-04-12 |
2024-04-14 |
mouse |
| Maciej Zadrozny, Patrycja Drapich, Anna Gasiorowska-Bien, Wiktor Niewiadomski, Charles R Harrington, Claude M Wischik, Gernot Riedel, Grazyna Niewiadomsk. Neuroprotection of Cholinergic Neurons with a Tau Aggregation Inhibitor and Rivastigmine in an Alzheimer's-like Tauopathy Mouse Model. Cells. vol 13. issue 7. 2024-04-12. PMID:38607082. |
basal forebrain cholinergic dysfunction, most likely linked with tau protein aggregation, is a characteristic feature of alzheimer's disease (ad). |
2024-04-12 |
2024-04-14 |
mouse |
| Maciej Zadrozny, Patrycja Drapich, Anna Gasiorowska-Bien, Wiktor Niewiadomski, Charles R Harrington, Claude M Wischik, Gernot Riedel, Grazyna Niewiadomsk. Neuroprotection of Cholinergic Neurons with a Tau Aggregation Inhibitor and Rivastigmine in an Alzheimer's-like Tauopathy Mouse Model. Cells. vol 13. issue 7. 2024-04-12. PMID:38607082. |
from a previous age profiling study, 6-month-old line 1 (l1) tau transgenic mice were characterized by a severe reduction in several cholinergic markers. |
2024-04-12 |
2024-04-14 |
mouse |
| Maciej Zadrozny, Patrycja Drapich, Anna Gasiorowska-Bien, Wiktor Niewiadomski, Charles R Harrington, Claude M Wischik, Gernot Riedel, Grazyna Niewiadomsk. Neuroprotection of Cholinergic Neurons with a Tau Aggregation Inhibitor and Rivastigmine in an Alzheimer's-like Tauopathy Mouse Model. Cells. vol 13. issue 7. 2024-04-12. PMID:38607082. |
we therefore assessed whether long-term pre-exposure with the acetylcholinesterase inhibitor rivastigmine alone and in conjunction with the tau aggregation inhibitor hmtm can reverse cholinergic deficits in l1. |
2024-04-12 |
2024-04-14 |
mouse |
| Maciej Zadrozny, Patrycja Drapich, Anna Gasiorowska-Bien, Wiktor Niewiadomski, Charles R Harrington, Claude M Wischik, Gernot Riedel, Grazyna Niewiadomsk. Neuroprotection of Cholinergic Neurons with a Tau Aggregation Inhibitor and Rivastigmine in an Alzheimer's-like Tauopathy Mouse Model. Cells. vol 13. issue 7. 2024-04-12. PMID:38607082. |
taken together, these data confirm a cholinergic phenotype in l1 tau transgenic mice that resembles the deficits observed in ad patients. |
2024-04-12 |
2024-04-14 |
mouse |
| Maciej Zadrozny, Patrycja Drapich, Anna Gasiorowska-Bien, Wiktor Niewiadomski, Charles R Harrington, Claude M Wischik, Gernot Riedel, Grazyna Niewiadomsk. Neuroprotection of Cholinergic Neurons with a Tau Aggregation Inhibitor and Rivastigmine in an Alzheimer's-like Tauopathy Mouse Model. Cells. vol 13. issue 7. 2024-04-12. PMID:38607082. |
the strongest phenotypic reversal coincided with a normalization of the tau load in the cortex and hippocampus of l1, suggesting that tau accumulation underpins the loss of cholinergic markers in the basal forebrain and its projection targets. |
2024-04-12 |
2024-04-14 |
mouse |
| Komaldeep Kaur, Yogesh A Kulkarni, Sarika Wairka. Exploring the potential of quercetin in Alzheimer's Disease: Pharmacodynamics, Pharmacokinetics, and Nanodelivery systems. Brain research. 2024-04-02. PMID:38565372. |
multiple complex pathways, such as oxidative stress, tau and amyloid-beta (aβ) pathology, and cholinergic dysfunction, are involved in the pathogenesis of alzheimer's disease. |
2024-04-02 |
2024-04-05 |
Not clear |
| Kushagra Nagori, Madhulika Pradhan, Mukesh Sharma, Ajazuddin, Hemant R Badwaik, Kartik T Nakhat. Current Progress on Central Cholinergic Receptors as Therapeutic Targets for Alzheimer's Disease. Current Alzheimer research. 2024-03-26. PMID:38529600. |
in ad, the extensive destruction of cholinergic neurons occurs by amyloid-β plaques and tau protein-rich neurofibrillary tangles. |
2024-03-26 |
2024-03-28 |
Not clear |
| Felix Langerscheidt, Michael Bell-Simons, Hans Zempe. Differentiating SH-SY5Y Cells into Polarized Human Neurons for Studying Endogenous and Exogenous Tau Trafficking: Four Protocols to Obtain Neurons with Noradrenergic, Dopaminergic, and Cholinergic Properties. Methods in molecular biology (Clifton, N.J.). vol 2754. 2024-03-21. PMID:38512687. |
differentiating sh-sy5y cells into polarized human neurons for studying endogenous and exogenous tau trafficking: four protocols to obtain neurons with noradrenergic, dopaminergic, and cholinergic properties. |
2024-03-21 |
2024-03-24 |
human |
| Varsha Mugundhan, Abirami Arthanari, Parameswari R Parthasarath. Protective Effect of Ferulic Acid on Acetylcholinesterase and Amyloid Beta Peptide Plaque Formation in Alzheimer's Disease: An In Vitro Study. Cureus. vol 16. issue 2. 2024-03-15. PMID:38487137. |
background ad is a progressive neurological condition marked by disrupted cholinergic signaling, accumulation of aβ peptide, and tau protein hyperphosphorylation. |
2024-03-15 |
2024-03-17 |
Not clear |
| Lorenza Guarnieri, Francesca Bosco, Antonio Leo, Rita Citraro, Ernesto Palma, Giovambattista De Sarro, Vincenzo Mollac. Impact of micronutrients and nutraceuticals on cognitive function and performance in Alzheimer's disease. Ageing research reviews. vol 95. 2024-02-09. PMID:38296163. |
another mechanism underlying the pathogenesis of ad is the abnormal phosphorylation of tau protein that accumulates at the level of neurofibrillary aggregates, and the areas most affected by this pathological process are usually the cholinergic neurons in cortical, subcortical, and hippocampal areas. |
2024-02-09 |
2024-02-14 |
Not clear |
| Zimeng Cheng, Tianyue Han, Jingtong Yao, Kaixuan Wang, Xue Dong, Fan Yu, He Huang, Menglin Han, Qinghong Liao, Siyu He, Weiping Lyu, Qi L. Targeting glycogen synthase kinase-3β for Alzheimer's disease: Recent advances and future Prospects. European journal of medicinal chemistry. vol 265. 2023-12-31. PMID:38160617. |
moreover, considering the close relationship between gsk-3β and other targets involved in cholinergic hypothesis, aβ aggregation hypothesis, tau hyperphosphorylation hypothesis, oxidative stress hypothesis, neuro-inflammation hypothesis, etc., diverse multifunctional molecules and multi-target directed ligands (mtdls) have also been disclosed. |
2023-12-31 |
2024-01-05 |
Not clear |
| Géssica Oliveira Mendes, Moysés Fagundes de Araújo Neto, Deyse Brito Barbosa, Mayra Ramos do Bomfim, Lorena Silva Matos Andrade, Paulo Batista de Carvalho, Tiago Alves de Oliveira, Daniel Luciano Falkoski, Eduardo Habib Bechelane Maia, Marcelo Siqueira Valle, Laila Cristina Moreira Damázio, Alisson Marques da Silva, Alex Gutterres Taranto, Franco Henrique Andrade Leit. Identification of Potential Multitarget Compounds against Alzheimer's Disease through Pharmacophore-Based Virtual Screening. Pharmaceuticals (Basel, Switzerland). vol 16. issue 12. 2023-12-23. PMID:38139772. |
the pathogenesis of ad seems to involve three main factors: deficiency in cholinergic transmission, formation of extracellular deposits of β-amyloid peptide, and accumulation of deposits of a phosphorylated form of the tau protein. |
2023-12-23 |
2023-12-25 |
Not clear |
| Vanshika Doshi, Garima Joshi, Sanjay Sharma, Deepak Choudhar. Gene therapy: an alternative to treat Alzheimer's disease. Naunyn-Schmiedeberg's archives of pharmacology. 2023-12-11. PMID:38078920. |
various hypotheses that may contribute to alzheimer's disease have been found during decades of survey, including tau theory, the amyloid theory, the cholinergic hypothesis, and the oxidative stress hypothesis. |
2023-12-11 |
2023-12-17 |
Not clear |
| Sumit Kumar, Amol Mahajan, Ramesh Ambatwar, Gopal Khati. Recent Advancements in the Treatment of Alzheimer's Disease: A Multitarget-directed Ligand Approach. Current medicinal chemistry. 2023-10-20. PMID:37861025. |
many pathogenic processes, including amyloid β aggregation, tau hyperphosphorylation, oxidative stress, neuronal death, and deterioration of the function of cholinergic neurons, are associated with its progression. |
2023-10-20 |
2023-11-08 |
Not clear |
| Adity Raturi, Vikas Yadav, Nasimul Hoda, Naidu Subbarao, Saif Ali Chaudhr. Journal of biomolecular structure & dynamics. 2023-10-12. PMID:37822182. |
these encompass theories such as the beta-amyloid hypothesis, cholinergic hypothesis, tau hypothesis, oxidative stress and more. |
2023-10-12 |
2023-10-15 |
Not clear |
| Yash Pal Singh, Navneet Kumar, Brijesh Singh Chauhan, Prabha Gar. Carbamate as a potential anti-Alzheimer's pharmacophore: A review. Drug development research. 2023-09-11. PMID:37694498. |
cholinergic neuronal loss, accumulation of amyloid plaque, metal ions dyshomeostasis, tau hyperphosphorylation, oxidative stress, neuroinflammation, and mitochondrial dysfunction are major hallmarks of ad. |
2023-09-11 |
2023-10-07 |
Not clear |
| Atamjit Singh, Karanvir Singh, Jashandeep Kaur, Ramanpreet Kaur, Aman Sharma, Jasleen Kaur, Uttam Kaur, Renu Chadha, Preet Mohinder Singh Bed. Pathogenesis of Alzheimer's Disease and Diversity of 1,2,3-Triazole Scaffold in Drug Development: Design Strategies, Structural Insights, and Therapeutic Potential. ACS chemical neuroscience. 2023-09-08. PMID:37683129. |
the review will provide (a) precise insight of various established targets of alzheimer's disease including cholinergic, amyloid, tau, monoamine oxidases, glutamate, calcium, and reactive oxygen species hypothesis and (b) design hypothesis, structure-activity relationships, and pharmacological outcomes of 1,2,3-triazole containing multifunctional anti-alzheimer's agents. |
2023-09-08 |
2023-10-07 |
Not clear |